Profusa Inc

Profusa’s $1.87 M convertible note conversion into 5.34 M shares injects equity, fuels regulatory progress, and positions the biotech for a public or merger move—watch capital use and insider activity.

Profusa’s CFO converts a $1.87 M debt into 5.34 M shares at $0.35 each, cutting leverage, boosting equity, and signaling a strategic shift toward acquisitions and a new $100 M cash line.

Profusa insider buying signals growth optimism as executives stack shares, driving confidence in its health‑care analytics platform and potential upside for investors.

Profusa’s zero‑cost insider share deal and new Lumee digital‑health platform could spark growth—see how equity, AI analytics, and value‑based care may boost value, not dilute shareholders.